EKF Diagnostics Showcases Range of Diabetes and Hematology POC Devices
|
By LabMedica International staff writers Posted on 01 Aug 2024 |
|
EKF Diagnostics (Cardiff, Wales, UK) is showcasing its range of diabetes and hematology point-of-care (POC) devices and connectivity software at ADLM 2024.
Among its diabetes POC devices, EKF is highlighting the Quo-Lab HbA1c semi-automated desktop POC analyzer for measuring glycated hemoglobin (HbA1c). The semi-automated analyzer has been designed specifically to meet the needs of diabetes clinics and laboratories in settings that demand low cost of operation and ease of use. EKF is also showcasing the Quo-Test fully automated desktop POC analyzer designed for easy and reliable HbA1c measurement for the monitoring and management of diabetes in a POC setting such as diabetes clinics and doctors’ surgeries. This fully automated hemoglobin A1c analyzer uses patented boronate affinity fluorescence quenching technology to measure glycated hemoglobin from a 4 μl sample taken from a capillary or venous whole blood. Also featuring at the show is the STAT-Site WB analyzer for the quantitative determination of β-ketones (Beta-Hydroxybutyrate or β-HB) and glucose in whole blood taken from capillary or venous samples.
Additionally, EKF is presenting its newly launched Biosen C-Line, an advanced version of its industry-leading rapid benchtop glucose and lactate analyzer. The new and updated analyzer has been designed to enhance usability with the latest color, touch screen, and advanced connectivity, enabling the Biosen C-Line to seamlessly connect with hospital and laboratory IT systems, via EKF Link, to ensure patient results are quickly and securely available to clinicians. Visitors to the EKF booth at the show can also experience the EKF Link middleware solution for healthcare providers that is designed to manage their POC analyzers and the generated data on one centralized platform. EKF Link is a flexible, open solution that can be interfaced with most vendors’ POC analyzers to permit the real-time management of data including patient test results, QC results, operator management, and analyzer configuration.
Within its portfolio of hematology POC devices, EKF is highlighting the DiaSpect Tm hand-held hemoglobin analyzer which is now powered by EKF Link, enabling new functions like hematocrit calculation, quality control management, and patient data management functions. The proven technology of DiaSpect Tm delivers laboratory-quality results in one second from the microcuvette being placed into the analyzer. In addition, EKF is featuring the Hemo Control POC hemoglobin analyzer which is designed to provide quantitative, lab-quality hemoglobin results in 25 seconds. Also featuring at the show is the HemataStat II microhematocrit centrifuge that provides a quantitative hematocrit reading for up to six blood samples from one 60-second spin.
Related Links:
EKF Diagnostics
Latest ADLM 2024 News
- HemoSonics Demonstrates Breakthrough in Point-Of-Care Viscoelastic Hemostasis Testing
- Cytovale Demonstrates 8-Minute Sepsis Diagnostic Test
- Inpeco Launches Next-Generation Total Lab Automation System
- Messe Düsseldorf Promotes International “MEDICAlliance” Portfolio at ADLM 2024
- Tianlong Showcases Latest Products in Molecular Diagnostics, Biochemistry, Immunology and POC Testing
- QuidelOrtho Demonstrates Advanced Diagnostic Laboratory Solutions across Healthcare Continuum
- HORIBA Unveils New Compact Hematology Analyzers with Combined ESR and CBC/Diff
- Beckman Coulter Introduces Latest Innovations in Clinical Diagnostics
- Abbott Demonstrates End to End Laboratory Solutions
- Werfen Introduces GEM Premier 7000 with iQM3 Blood Gas Testing System
- Thermo Fisher Showcases Diagnostics Innovation Across Therapeutic Areas
- Siemens Demonstrates Human-Centered Engineering and Automation for Laboratory Testing
- Roche Showcases Solutions for Laboratories of the Future
- POC Electrical Sensing-Based Blood Testing Technology Unveiled at ADLM 2024
- World's First 5-Minute Real-Time PCR Instrument Debuts at ADLM 2024
- ADLM 2024 Showcases Breakthrough Innovations Shaping Future of Clinical Testing
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read more
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channel
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Microbiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more
AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
Pathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read more
Technology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read more
Aptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more